Market Place
Sourcing Support
Regen BioPharma Expands Vision For HemaXellerate™ Phase 1 Trial
19 Nov 2024 //
GLOBENEWSWIRE
Regen BioPharma To Present At Emerging Growth Conference
23 Sep 2024 //
GLOBENEWSWIRE
Regen Plans to Move Forward with HemaXellerate into Clinical Ph 1
02 Apr 2024 //
PR NEWSWIRE
Regen to Present at the Emerging Growth Conference on January 10, 2024
08 Jan 2024 //
PR NEWSWIRE
Regen BioPharma to Discuss Confirmation Study Results on Its DuraCar Program
30 Oct 2023 //
PR NEWSWIRE
Regen Receives Second Phase Data on Duracar CAR-T Cell Therapy Program
25 Oct 2023 //
PR NEWSWIRE
Regen to Present at the Emerging Growth Conference on February 22, 2023
21 Feb 2023 //
PR NEWSWIRE
Regen Bio to Present at the Emerging Growth Conference on February 8, 2023
07 Feb 2023 //
PR NEWSWIRE
Regen Leverages Exosome to Broaden Survivin Cancer Immunotherapy Portfolio
21 Jan 2023 //
PR NEWSWIRE
Regen issues Message to the Shareholders from the Chairman And CEO
19 Dec 2022 //
PRNEWSWIRE
Regen BioPharma, Inc. Progresses Its DuraCAR Therapeutic
18 Nov 2022 //
PRNEWSWIRE
Regen BioPharma, Inc. Explores the CAR-T Therapeutic Space
26 Oct 2022 //
PRNEWSWIRE
Regen Files Provisional Patent on CAR-T Cell Capable of Educating Naïve T Cells
05 Oct 2022 //
PRNEWSWIRE
Regen BioPharma Develops Novel Means of Using CAR-T cell Immunotherapy
25 Aug 2022 //
PRNEWSWIRE
Regen BioPharma, Inc. Develops Novel Dedifferentiation Approach
11 Aug 2022 //
PRNEWSWIRE
Regen BioPharma Files Provisional Patent for Survivin mRNA Cancer Vaccine
26 Jul 2022 //
PRNEWSWIRE
Regen BioPharma. Responds to Numerous Requests for Updates on its IP Portfolio
16 Mar 2022 //
PRNEWSWIRE
Regen BioPharma Announces Program to Fast-Track its Checkpoint Inhibitor Program
10 Mar 2022 //
PRNEWSWIRE
Oncology Pharma, Regen Bio to Jointly Develop Modified mRNA anti-Cancer Vaccine
14 Feb 2022 //
ACCESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.